**Name of journal:** World Journal of Hepatology

**Manuscript NO:** 90603

**Title:** Changes in bacterial composition and metabolic pathways associated with ornithine aspartate intake in a rat model of metabolic dysfunction-associated steatotic liver disease

**Provenance and peer review:** Unsolicited Manuscript; Externally peer reviewed

**Peer-review model:** Single blind

**Reviewer’s code:** 02809917

**Position:** Peer Reviewer

**Academic degree:** MD

**Professional title:** Director

**Reviewer’s Country/Territory:** China

**Author’s Country/Territory:** Brazil

**Manuscript submission date:** 2023-12-11

**Reviewer chosen by:** Huo Liu

**Reviewer accepted review:** 2024-01-17 11:16

**Reviewer performed review:** 2024-01-21 15:20

**Review time:** 4 Days and 4 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>[ ] Grade A: Excellent</th>
<th>[ ] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
<th>[ ] Grade D: Fair</th>
<th>[ ] Grade E: Do not publish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Novelty of this manuscript</td>
<td>[ ] Grade A: Excellent</td>
<td>[ ] Grade B: Good</td>
<td>[ ] Grade C: Fair</td>
<td>[ ] Grade D: No novelty</td>
<td></td>
</tr>
</tbody>
</table>
SPECIFIC COMMENTS TO AUTHORS
This study examined the effect of ornithine aspartate (LOLA) on metabolic-associated liver disease (MASLD) in rats. This study is an extension of authors efforts in the field (PMID 32982365, 35070008, 36551202), focusing on gut microbiota. In general, the experiments were logically designed and well conducted, and the comprehensive bioinformatics including R packages were used to analyze the data. The results obtained are sound and could add to our understanding of pharmacological effects of LOLA against MASLD. Listed below are specific comments: 1. General characteristics (Table S1) should be used as Table 1, as theses basic data are essential for understanding the effects of LOLA on MASLD. Two comments on the Table: (1) “0,001” should be 0.001; (2) “20,5222” could be “20.52”, “2921,3080” could be “2921” per “4 effective number rule”. 2. The important information from their prior work (PMID 36551202, Ref 11) on LOLA on MASLD should be adequately referenced to give readers a big picture of the study. 3.
Others

a. Line 49 “Ornithine Aspartate” could be “ornithine aspartate” to be consistent with their prior publication (e.g., Ref 11) and the text (e.g., line 85).
b. Line 240, 301, 317, 326: “L-ornithine, L-aspartate” should be “L-ornithine, L-aspartate” to be consistent throughout the manuscript.
c. Line 54, 109, 119, 122: Add a space between number and units as “200 mg, 10 µg” throughout the manuscript.